“Improving Access to Clinical Trials Act” Passes U.S. House, Heads to President for Signature
September 23, 2010
Today the U.S. House of Representatives passed the “Improving Access to Clinical Trials Act” (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.
Today the U.S. House of Representatives passed the “Improving Access to Clinical Trials Act” (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.
The bill, which passed the Senate Aug. 5, now goes to President Obama’s desk for his signature. He is expected to sign it.
This legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits. Passage of this legislation is particularly important for people with CF, a rare genetic disease.
This legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits. Passage of this legislation is particularly important for people with CF, a rare genetic disease.
A limited patient population makes it challenging to find enough people to participate in research studies evaluating the effectiveness of promising new drugs.
“Because of this groundbreaking legislation, people with CF and other rare diseases will no longer be forced to choose between critical health care coverage and participation in research that could lead to the development of a cure for our most serious illnesses,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation.
To read more visit www.cff.org
1 comment:
this is GREAT! =) Bring on more trials and new drugs baby! We need to cure CF!
Post a Comment